Should all patients with hypertension be worried about developing severe coronavirus disease 2019 (COVID-19)?
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: Hypertension, the most common comorbidity among coronavirus disease 2019 (COVID-19) patients, is accompanied by worse clinical outcomes, but there is lack of evidence about prognostic factors among COVID19 patients with hypertension. We have come up with some prognostic factors to predict the severity of COVID-19 among hypertensive patients. In addition, epidemiologic, clinical and laboratory differences among COVID-19 patients with and without underlying hypertension were evaluated. Methods: Medical profiles of 598 COVID-19 cases were analyzed. Patients were divided into two comparative groups according to their positive or negative history of hypertension. Then, epidemiologic, clinical, laboratory and radiological features and also clinical outcomes were compared. Results: 176 (29.4%) patients had underlying hypertension. Diabetes was significantly higher in hypertensive group [72 (40.9%) vs 76 (18%)] (P-value: 0.001). Cardiovascular and renal disorders were significantly higher in hypertensive patients. (P-value: 0.001 and 0.013 respectively). In COVID-19 patients with hypertension, severe/critical types were significantly higher. [42(23.8%) vs. 41(9.7%)], (P-value: 0.012). In the logistic regression model, Body mass index > 25 (ORAdj: 1.8, 95% CI: 1.2 to 2.42; P-value: 0.027), age over 60 (ORAdj: 1.26, 95% CI: 1.08 to 1.42; P-value: 0.021), increased hospitalization period (ORAdj: 2.1, 95% CI: 1.24 to 2.97; P-value: 0.013), type 2 diabetes (ORAdj: 2.22, 95% CI: 1.15 to 3.31; P-value: 0.001) and chronic kidney disease (ORAdj: 1.83, 95% CI: 1.19 to 2.21; P-value: 0.013) were related with progression of COVID-19. Conclusion: Hypertensive patients with Age > 60-year-old, BMI > 25 Kg/m2 , CVD, diabetes and chronic kidney disease are associated with poor outcomes in those with COVID-19 infection.
Abstract
Background: Hypertension, the most common comorbidity among coronavirus disease 2019 (COVID-19) patients, is accompanied by worse clinical outcomes, but there is lack of evidence about prognostic factors among COVID19 patients with hypertension. We have come up with some prognostic factors to predict the severity of COVID-19 among hypertensive patients. In addition, epidemiologic, clinical and laboratory differences among COVID-19 patients with and without underlying hypertension were evaluated. Methods: Medical profiles of 598 COVID-19 cases were analyzed. Patients were divided into two comparative groups according to their positive or negative history of hypertension. Then, epidemiologic, clinical, laboratory and radiological features and also clinical outcomes were compared. Results: 176 (29.4%) patients had underlying hypertension. Diabetes was significantly higher in hypertensive group [72 (40.9%) vs 76 (18%)] (P-value: 0.001). Cardiovascular and renal disorders were significantly higher in hypertensive patients. (P-value: 0.001 and 0.013 respectively). In COVID-19 patients with hypertension, severe/critical types were significantly higher. [42(23.8%) vs. 41(9.7%)], (P-value: 0.012). In the logistic regression model, Body mass index > 25 (ORAdj: 1.8, 95% CI: 1.2 to 2.42; P-value: 0.027), age over 60 (ORAdj: 1.26, 95% CI: 1.08 to 1.42; P-value: 0.021), increased hospitalization period (ORAdj: 2.1, 95% CI: 1.24 to 2.97; P-value: 0.013), type 2 diabetes (ORAdj: 2.22, 95% CI: 1.15 to 3.31; P-value: 0.001) and chronic kidney disease (ORAdj: 1.83, 95% CI: 1.19 to 2.21; P-value: 0.013) were related with progression of COVID-19. Conclusion: Hypertensive patients with Age > 60-year-old, BMI > 25 Kg/m2 , CVD, diabetes and chronic kidney disease are associated with poor outcomes in those with COVID-19 infection.
참고문헌 (35)
- "Coronavirus Update (Live): 4, 852 Cases and 303,584 Deaths from COVID-19 Virus Pandemic - Worldometer"[URL]
- Paules CI, "Coronavirus infections-more than just the common cold", Jama, 323(8), pp.707~708 (2020)
- Lum LHW, "Outbreak of COVID-19-an urgent need for good science to silence our fears?", Singap Med J., 61(2), pp.55~ (2020)
- Chen N, "Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China : a descriptive study", Lancet, 395(10223), pp.507~513 (2020)
- Qian, G. -Q., "Epidemiologic and clinical characteristics of 91hospitalized patients with COVID-19 in Zhejiang, China: a retrospective, multi-Centre case series", QJM: An International Journal of Medicine (2020)
- Xu Y-H, "Clinical and computed tomographic imaging features of novel coronavirus pneumonia caused by SARS-CoV-2", J Infect (2020)
- Baud D, "Real estimates of mortality following COVID-19 infection", Lancet Infect Dis (2020)
- Jiang X, "Does SARS-CoV-2 has a longer incubation period than SARS and MERS?", J Med Virol (2020)
- Guan W-J, "Clinical characteristics of coronavirus disease 2019 In China", New England journal of medicine, 382(18), pp.1708~1720 (2020)
- Liu K, "Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province", Chin Med J (2020)
- Huang, Y., "Clinical characteristics of laboratory confirmed positive cases of SARS-CoV-2 infection in Wuhan, China: A retrospective single center analysis", Travel medicine and infectious disease (2020)
- Chen T, "Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study", Bmj, 368 (2019)
- Emami A, "Prevalence of underlying diseases in hospitalized patients with COVID-19: a systematic review and meta-analysis", Archives of academic emergency medicine, 8(1) (2020)
- Zhou F, "Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study", Lancet (2020)
- Grasselli G, "Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy region, Italy", Jama, 323(16), pp.1574~1581 (2020)
- Fang, L., "Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?", The Lancet. Respiratory Medicine (2020)
- Li B, "Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China", Clin Res Cardiol, pp.1~8 (2020)
- Schiffrin, E.L., "Hypertension and COVID-19" (2020), Oxford University Press US
- Badawi A, "Prevalence of comorbidities in the Middle East respiratory syndrome coronavirus(MERS-CoV) : a systematic review and meta-analysis", Int J Infect Dis, 49, pp.129~133 (2016)
- Zheng Y-Y, "COVID-19 and the cardiovascular system", Nat Rev Cardiol, 17(5), pp.259~260 (2020)
- Rees, E.M., "COVID-19 length of hospital stay: a systematic review and data synthesis" (2020)
- Gabb GM, "Guideline for the diagnosis and management of hypertension in adults—2016", Med J Aust, 205(2), pp.85~89 (2016)
- Wan Y, "Receptor recognition by the novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS coronavirus", J Virol, 94(7) (2020)
- Zu ZY, "Coronavirus disease 2019 (COVID-19): a perspective from China", Radiology, pp.200490~ (2020)
- Xiang, T. X., "Analysis of clinical characteristics of 49patientswith novel coronavirus pneumonia in Jiangxi Province", Chinese J Respir Crit Care Med (2020)
- Wang, Z., "Clinical features of 69 cases with coronavirus disease 2019in Wuhan, China", Clinical Infectious Diseases (2019)
- Qin, C., "Dysregulation of immune response in patients with COVID-19in Wuhan", China. Clinical Infectious Diseases (2020)
- Liu W, "Analysis of factors associated with disease outcomes in hospitalized patients with 2019 novel coronavirus disease", Chin Med J. (2019)
- Chen C, "Analysis of myocardial injury in patients with COVID-19 and association between concomitant cardiovascular diseases and severity of COVID-19", Zhonghua xin xue guan bing za zhi, 48, pp.E008~ (2020)
- Shi, S., "Assoeciation of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China", JAMA cardiology (2020)
- Guo, T., "Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19)", JAMA Cardiol (2020)[DOI]
- Lippi G, "Hypertension and its severity or mortality in coronavirus disease 2019(COVID-19) : a pooled analysis", Pol Arch Intern Med, 130, pp.304~309 (2020)
- Wang D, "Clinical characteristics of 138 hospitalized patients with 2019novel coronavirus-infected pneumonia in Wuhan, China", Jama, 323(11), pp.1061~1069 (2020)
- Henry, B.M., "Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis", Clinical Chemistry and Laboratory Medicine (CCLM) (2020)
- Li XC, "The vasoprotective axes of the renin-angiotensin system : physiological relevance and therapeutic implications in cardiovascular, hypertensive and kidney diseases", Pharmacol Res, 125, pp.21~38 (2017)